Impax Laboratories Inc. Message Board
-
They have another $100M shelf to be announced . they need money to purchase new power projects
- Reply to
Question for shorts: Why Goldman Sachs purchased 100K shares if UNXL has quality problem?
by dbenporat •Jun 3, 2013 2:20 PMand why VP of Samsung joint UNXL?
- Reply to
Question for shorts: Why Goldman Sachs purchased 100K shares if UNXL has quality problem?
by dbenporat •Jun 3, 2013 2:20 PMAnd why Kodak announced on its website: Kodak to Manufacture and Supply UniBoss Touch Sensors for UniPixel
Kodak technology to enable UniPixel to scale production to meet accelerating demand; Positions both companies for faster growth in dynamic $16 billion global touch sensor market - Reply to
Question for shorts: Why Goldman Sachs purchased 100K shares if UNXL has quality problem?
by dbenporat •Jun 3, 2013 2:20 PMAnd why Bank of America Merrill Lynch own 5.4% as 3/12/31. Merrill Lynch has an excellent research department. See MSN ownership for UNXL
- Reply to
Question for shorts: Why Goldman Sachs purchased 100K shares if UNXL has quality problem?
by dbenporat •Jun 3, 2013 2:20 PMAnd why Willington Capital , the third best fund in 2012 owns 11.5% of shares.
-
Goldman Sachs purchased 100K shares of UNXL as of 3/30/2013. Goldman is the best investment bank and well known for its research team. They wont buy so many shares if UNXL has severe product quality problems.
-
So who we should trust: Dell , Intel , Kodak , Samsung , Bank of America, Merrill Lynch Willington , Goldman or SeekingAlpha articles paid by short sellers?
WE SHOULD TRUST THE SA ARTICLE AUTHOR WHO IS PAID BY SHORT SELLER AND MOST LIKELY IS LOCATED OUT OF US -
I received email today stating "there will be today a proper respond to the allegations of seekingalpha article" . i hope no bad news is waiting for us
GLTA - Reply to
Reuters news: JACO is evaluating options to boost cash position (see link)
by dbenporat •May 20, 2013 2:58 PMJACO is evaluating options to boost cash position. most likable by selling stock after 60% rally
-
JA Solar's margin bet pays off, shares surge
2:34pm EDT
Mon May 20, 2013
* Gross margins positive for first time in three quarters
* Co says remains committed to meeting all debt obligations
* Says still evaluating options to boost cash position
* Backs full-year shipments outlook
* Shares jump 51 percent, touches new year-high of $8.40 (Adds details from conference call, updates share move)
May 20 (Reuters) - JA Solar Holdings Co Ltd's focus on margins over volumes paid off as the Chinese solar products maker halved its operating loss in the first quarter by selling more panels in high-margin Japan. -
It will be down 30% tomorrow
-
0.85 LOSS VS. ESTIMATE OF 1.07 LOSS. WHY SLIGHTLY LESS LOSS JUSTIFIES 55% RALLY?
EU Levy is still likely to be finalized this week and then all solar stocks will crash 30% in single day.
Any rational response? What I am missing here ? -
I sold at 8.29 because of possible dilution after 4PM
-
Anybody else thinks stock sale is likely after 4PM?
-
VERY LIKELY . JASO needs cash for its next debt payment and for paying its 17000 employees.
-
0.85 LOSS VS. ESTIMATE OF 1.07 LOSS. WHY SLIGHTLY BETTER LOSS JUSTIFIES 50% RALLY?
Any rational response? What I am missing here ? - Reply to
A PR for a new data analysis for Tivo is imminent . A PR maybe today after long quiet period?
by dbenporat •May 15, 2013 2:47 PMI talked with a PHD friend in Irvine who is working with Spectrum Pharmaceuticals and asked him to research for me about Tivo of AVEO. He researched and said based on FDA announcements , it is likely that FDA will ask a data analysis of last P3 to exclude the crossover patients.
- Reply to
A PR for a new data analysis for Tivo is imminent . A PR maybe today after long quiet period?
by dbenporat •May 15, 2013 2:47 PM5/15/13 6PM
AVEO and Astellas Announce Presentations of Tivozanib Clinical Data at 2013 American Society of Clinical Oncology Annual Meeting.
In the presentation, AVEO and Astellas will announce a new data analysis to avoid a new expensive phase III. -
FDA & AVEO are considering a new data analysis to avoid a new expensive P3. Cancer patients need a better drug like Tivo and FDA doctors know the truth about efficacy of Tivo
-
TIVO has longer progression free survival and less side effects than other 2 kidney cancer drugs.
Aveo should have done a better P3 design to ensure against anomalies and crossovers. But the result is that kidney cancer patients will be denied access to a drug that provides longer progression free survival than any other drug on the market . FDA panel failed TIVO due to bad P3 design and now kidney cancer patients are stuck with explosive diarrhea and other horrible side effects. Maybe a thorough data analysis could solve the problem caused by bad P3 design.